Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × selinexor × Dermatologic × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 24 Other hematologic neoplasm 22 Lymphoid 15 Sarcoma 7 Thoracic 5 Gastrointestinal 5 Myeloid 4 Gynecologic 3 Genitourinary 3 Other solid neoplasm 2 Head & Neck 1 Endocrine 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

Nivolumab 148 Ipilimumab 134 pembrolizumab 131 Cyclophosphamide 115 aldesleukin 63 Radiotherapy 62 fludarabine phosphate 61 Interleukin-2 61 Biopsy 48 Blood Specimen Collection 44 Temozolomide 42 fludarabine 40 Peripheral Blood Stem Cell Transplantation 40 Radiosurgery 39 trametinib 35 Vemurafenib 34 dabrafenib 30 sargramostim 29 Bevacizumab 29 Magnetic Resonance Spectroscopy 28 Aminolevulinic Acid 28 Mycophenolic Acid 26 Photochemotherapy 25 Whole-Body Irradiation 24 Surveys and Questionnaires 24 Specimen Handling 24 Imiquimod 24 Cyclosporine 23 Melphalan 22 Introns 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02120222 2023-04-04

KPT-330

Ohio State University Comprehensive Cancer Center

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡